Intellia Therapeutics, Inc. (NASDAQ:NTLA) to Post FY2023 Earnings of ($4.90) Per Share, SVB Leerink Forecasts

Intellia Therapeutics, Inc. (NASDAQ:NTLAGet Rating) – Stock analysts at SVB Leerink increased their FY2023 earnings per share (EPS) estimates for shares of Intellia Therapeutics in a research note issued to investors on Monday, September 19th. SVB Leerink analyst M. Foroohar now forecasts that the company will post earnings per share of ($4.90) for the year, up from their previous estimate of ($4.92). SVB Leerink currently has a “Outperform” rating and a $158.00 target price on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.83) per share.

Intellia Therapeutics (NASDAQ:NTLAGet Rating) last issued its earnings results on Thursday, August 4th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02). The company had revenue of $14.00 million during the quarter, compared to analyst estimates of $9.50 million. Intellia Therapeutics had a negative return on equity of 40.23% and a negative net margin of 883.17%. The business’s revenue was up 115.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.01) earnings per share.

A number of other brokerages have also recently issued reports on NTLA. Credit Suisse Group lifted their target price on Intellia Therapeutics to $101.00 in a report on Tuesday, August 9th. The Goldman Sachs Group decreased their target price on Intellia Therapeutics from $206.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, May 24th. BMO Capital Markets initiated coverage on Intellia Therapeutics in a research report on Thursday, June 16th. They issued a “market perform” rating and a $54.00 target price for the company. StockNews.com raised Intellia Therapeutics to a “sell” rating in a research report on Friday, August 5th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $146.00 price target on shares of Intellia Therapeutics in a research report on Friday, September 16th. Two analysts have rated the stock with a sell rating, one has given a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $123.82.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA opened at $62.53 on Wednesday. The stock’s fifty day simple moving average is $62.95 and its 200 day simple moving average is $58.02. Intellia Therapeutics has a 52-week low of $37.08 and a 52-week high of $155.63.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Prospera Financial Services Inc acquired a new position in Intellia Therapeutics during the 1st quarter worth $32,000. Newbridge Financial Services Group Inc. lifted its holdings in Intellia Therapeutics by 49.2% during the 1st quarter. Newbridge Financial Services Group Inc. now owns 776 shares of the company’s stock worth $56,000 after buying an additional 256 shares in the last quarter. Herold Advisors Inc. acquired a new position in Intellia Therapeutics during the 1st quarter worth $62,000. Penserra Capital Management LLC acquired a new position in Intellia Therapeutics during the 1st quarter worth $97,000. Finally, Steward Partners Investment Advisory LLC lifted its holdings in Intellia Therapeutics by 10.2% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 2,368 shares of the company’s stock worth $123,000 after buying an additional 220 shares in the last quarter. 88.18% of the stock is owned by institutional investors and hedge funds.

About Intellia Therapeutics

(Get Rating)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.

Read More

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.